Related Experiment Video

Updated: Jan 12, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.0K

KIAA1429 in non-small cell lung cancer: bridging m6A epigenetics to therapeutic innovation

Hui Liu1, Ke Shi2, Liang Liu3,4

  • 1Department of Ultrasound Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, China.

Frontiers in Surgery
|November 5, 2025
PubMed

Insights

KIAA1429 drives non-small cell lung cancer (NSCLC) progression and resistance via epigenetic mechanisms. Targeting KIAA1429 offers a promising strategy for precision therapy in NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • KIAA1429 is a key component of the m6A methyltransferase complex.
  • Its overexpression is linked to aggressive non-small cell lung cancer (NSCLC) and poor prognosis.
  • KIAA1429 influences tumorigenesis, metastasis, and therapeutic resistance.

Purpose of the Study:

  • To review the role of KIAA1429 in NSCLC pathogenesis.
  • To elucidate KIAA1429's m6A-dependent regulation of downstream targets.
  • To highlight KIAA1429 as a potential therapeutic target for NSCLC.

Main Methods:

  • Comprehensive literature review on KIAA1429 in NSCLC.
  • Analysis of KIAA1429 expression patterns and clinical correlations.
  • Examination of KIAA1429's molecular mechanisms and downstream effectors.

Main Results:

  • KIAA1429 overexpression correlates with advanced NSCLC and poor outcomes.
  • KIAA1429 modulates key effectors like HOXA1, DAPK3, and BTG2 via m6A.
  • Dysregulated KIAA1429 drives malignant transformation in NSCLC.

Conclusions:

  • KIAA1429 is a critical epigenetic regulator in NSCLC.
  • Targeting KIAA1429 presents a novel avenue for precision oncology in NSCLC.
  • Further research into KIAA1429 inhibitors is warranted.
Keywords:
KIAA1429gefitinib resistancem6A modificationmolecular targetnon-small cell lung cancer

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K